Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/32859
Title: Dornase Alfa Improves the Health-Related Quality of Life Among Brazilian Patients With Cystic Fibrosis-A One-Year Prospective Study
Authors: Rozov, Tatiana [UNIFESP]
Oliveira, Viviane Ziebell de
Santana, Maria Angelica
Adde, Fabiola Villac
Mendes, Rita Heloisa
Paschoal, Ilma Aparecida
Caldeira Reis, Francisco J.
Shinzato Higa, Laurinda Yoko
Castro Toledo, Antonio Carlos de
Pahl, Marcia
Pulmozyme Study Grp
Universidade Federal de São Paulo (UNIFESP)
Universidade Federal do Pará (UFPA)
HEOM
Universidade de São Paulo (USP)
Universidade Estadual de Campinas (UNICAMP)
CGP
Fiocruz MS
UNIFENAS BH
Roche Brasil
Keywords: cystic fibrosis
rhDNase
quality of life
treatment
Issue Date: 1-Sep-2010
Publisher: Wiley-Blackwell
Citation: Pediatric Pulmonology. Hoboken: Wiley-liss, v. 45, n. 9, p. 874-882, 2010.
Abstract: Background: Health-related quality of life (HRQOL) measurements provide valuable information about the psychological and social impact of treatment on patients with cystic fibrosis (CF). This study evaluated the HRQOL of Brazilian patients with CF and assessed the changes in HRQOL domains over 1 year after dornase alfa (Pulmozyme) introduction.Patients and Methods: One hundred fifty-six stable patients with CF and 89 caregivers answered the Portuguese-validated version of the Cystic Fibrosis Questionnaire-Revised (CFQ-R) at baseline (T(0)), and at 3 (T(1)), 6 (T(2)), 9 (T(3)), and 12 (T(4)) months of follow-up. Eighteen patients were excluded because they did not fulfill the inclusion criteria. the patients were analyzed in two groups: those aged 6-11 years and those aged 14 years and older. ANOVA for observed repeated results and the last observation carried forward (LOCF) method for missing data were used for the statistical analysis.Results: After 1 year of follow-up, there was significant improvement in respiratory symptoms (T(4) - T(0) = 8.1; 95% confidence interval (95% CI) = [2.1;14.0]; effect size (ES) = 0.35; P<0.001), Emotional Functioning (T(4) - T(0) = 5.6; 95% CI = [1.1;10.1]; ES = 0.31; P<0.05), Social Functioning (T(4) - T(0) = 6.0; 95% CI = [1.3;11.7]; ES = 0.31; P<0.05), Body Image (T(4) - T(0) = 11.9; 95% CI = [4.1;19.7]; ES = 0.42; P<0.05), and Treatment Burden (T(4) - T(0) = 5.3; 95% CI = [0.3;10.3]; ES = 0.24; P<0.05) domains in the younger group. A significant improvement in Role Functioning (T(4) - T(0) = 6.1; 95% CI = [1.1;11.1]; ES = 0.40; P<0.05), Body Image (T(4) - T(0) = 12.6; 95% CI = [3.5;21.7]; ES = 0.46; P<0.05), and Weight (T(4) - T(0) = 11.7; 95% CI = [1.8;21.6]; ES = 0.40; P<0.05) was obtained in the older group. the caregivers' CFQ-R showed improvements in the Digestive Symptoms (T(4) - T(0) = 5.5; 95% CI = [1.5;9.4]; ES = 0.30; P<0.05), Respiratory Symptoms (T(4) - T(0) = 7.6; 95% CI = [3.9;11.4]; ES = 0.48; P< 0.05), and Weight (T(4) - T(0) = 10.1; 95% CI = [1.6;18.6]; ES = 0.26; P<0.05) domains.Conclusion: the introduction of dornase alfa improved the HRQL of the patients with CF during the first year of treatment. Pediatr Pulmonol. 2010; 45:874-882. (C) 2010 Wiley-Liss, Inc.
URI: http://repositorio.unifesp.br/handle/11600/32859
ISSN: 8755-6863
Other Identifiers: http://dx.doi.org/10.1002/ppul.21267
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.